Early oral anticoagulation is non-inferior to delayed treatment in ...
Dec 11, 2024 · 1. Early DOAC therapy within 4 days was non-inferior to delayed therapy for the composite outcome of recurrent ischemic or unclassified stroke, symptomatic intracranial hemorrhage, and systemic embolism at 90 days. Evidence Rating Level: 1 (Excellent) Study Rundown: The optimal timing for starting anticoagulation in patients with acute ischemic stroke and atrial fibrillation remains unclear,
Amivantumab plus lazertinib improves survival in EGFR-mutated …
Nov 27, 2024 · 1. In this randomized trial, amivantamab-lazertinib led to significantly longer progression-free survival than osimertinib therapy for mutated advanced non-small-cell lung cancer (NSCLC). 2. Amivantamab-lazertinib showed superior efficacy to osimertinib as first-line therapy for epidermal growth factor receptor (EGFR) mutated advanced NSCLC. Evidence Rating Level: 1 (Excellent) Study Rundown ...
Point of care C-reactive protein testing may be useful in guiding ...
Dec 6, 2024 · 1. C-reactive protein (CRP)-point-of-care tests can be used to guide antibiotic prescribing in primary care for patients with acute exacerbations of COPD with no reduction in patient outcome Evidence Rating Level: 1 (Excellent) About 80% of patients presenting with acute exacerbations of chronic obstructive pulmonary disease (AECOPD) to primary care are often given antibiotics that
Axonal injury may occur up to 9 years prior to symptom onset in ...
Dec 3, 2024 · 1. Multiple sclerosis patients can sustain axonal injury up to 9 years before symptom onset. 2. Until symptom onset, physical and mental well-being are comparable between affected and unaffected individuals. Evidence Rating Level: 3 (Average) Multiple sclerosis (MS) has an unclear mechanism and onset with physiological changes occurring well …
Adjuvant durvalumab therapy improves survival in limited-stage …
Nov 21, 2024 · 1. In this randomized controlled trial, adjuvant therapy with durvalumab led to improved overall and progression-free survival compared to placebo in patients with limited-stage small cell lung cancer (SCLC). 2. Durvalumab had a tolerable safety profile, with a comparable incidence of adverse effects to the placebo group. Evidence Rating Level: 1 (Excellent) Study Rundown: Small
Influenza vaccination may reduce secondary infection spread …
Dec 1, 2024 · 1. Influenza vaccination was associated with a reduced risk of secondary influenza infections among household contacts, with an estimated effectiveness of 21%. Evidence Rating Level: 2 (Good) Influenza vaccinations are recommended for all individuals aged 6 months and older in the United States for the prevention of influenza infection. However, while the effectiveness of influenza
RAMOSE Phase II trial finds promising results for osimertinib and ...
Dec 10, 2024 · 1. Treatment of patients with tyrosine kinase inhibitor (TKI)-naïve epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) with osimertinib and ramucirumab resulted in a significantly longer progression-free survival (PFS) compared with osimertinib alone. Evidence Rating Level: 1 (Excellent) Study Rundown: The current standard of care for patients with advanced EGFR ...
Invasive treatment not superior to medical therapy in older adults …
Dec 10, 2024 · 1. In this randomized controlled trial, in older adults with non-ST-segment elevation myocardial infarction (NSTEMI), invasive treatment did not significantly reduce the composite risk of cardiovascular death or nonfatal MI compared to conservative treatment. 2. There were fewer occurrences of fatal or nonfatal MI in patients in the invasive-strategy group than in the conservative-strategy group.
Multi-component sleep-mood group interventions may improve …
Nov 14, 2024 · 1. In this pilot randomized controlled trial, the Sleep Mood Intervention: Life Effectively (SMILE) intervention was associated with improvements in insomnia in university students. Evidence rating level: 1 (Excellent) Insomnia has a major burden on public health and can have serious long-term physical and mental health effects if left untreated.
Intellia Therapeutics: NTLA-2002 CRISPR-based therapy reduces …
Nov 25, 2024 · CRISPR gene editing based treatment reduced HAE attacks rates by up to 80%. NTLA-2002 was well tolerated by patients. The Latest In a phase 2, randomized, double-blind, placebo-controlled study done by Intellia Therapeutics the efficacy and safety of NTLA-2002 was tested. The study involved 27 participants who were randomized to receive either a 25mg dose,